Trastuzumab

Second-Line Trastuzumab Active in HER2-positive Advanced/Recurrent Gastric Cancer

Second-Line Trastuzumab Active in HER2-positive Advanced/Recurrent Gastric Cancer

By

Second-line treatment with paclitaxel/trastuzumab showed promising activity in trastuzumab-naïve patients with HER2-positive gastric cancer.

Pathologic Complete Response Increases Survival in HER2-positive Breast Cancer

By

The NeoALTTO study showed pathologic complete response increased survival in HER2-positive breast cancer.

High Tumor HER2 Predicts Greatest Benefit from T-DM1 Breast Cancer Treatment

By

Women with metastatic, HER2-positive breast cancer with tumors that express high levels of HER2 derived the greatest survival benefit from treatment with trastuzumab emtansine (T-DM1), according to research presented at AACR 2013.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs